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Interpretation of erythropoietin levels in patients with various
degrees of renal insufficiency and anemia.
Background. Chronic renal failure leads to hyporegenerative
anemia due to erythropoietin deficiency. The creatinine clear-
ance and hemoglobin levels, at which anemia treatment with
recombinant erythropoietin should be started, are unclear. In-
terpretation of serum erythropoietin levels in the context of
renal insufficiency remains controversial and was addressed in
this study.
Methods. Three hundred and ninety-five patients were ran-
domly chosen out of over 5000 consecutive patients investigated
by coronary angiography at a single center between 1997 and
2001. Laboratory values and clinical information were prospec-
tively collected in a central registry. Serum samples were frozen
before angiography and now used to measure serum erythro-
poietin levels and evaluate the relationship between erythro-
poietin and hemoglobin levels in the context of various degrees
of renal insufficiency.
Results. The patients with the lowest renal function (creati-
nine clearance<20 mL/min) had significantly lower hemoglobin
levels than the group with normal renal function. However, ery-
thropoietin levels were identical indicating a lower set point for
erythropoietin regulation. Above a creatinine clearance of 40
mL/min a significant inverse correlation between erythropoi-
etin and hemoglobin levels was observed and described with the
formula erythropoietin [U/L] = 2.5 × (140 − hemoglobin [g/L])
or alternatively erythropoietin (U/L) = −2.5 × hemoglobin
(g/L). Below 40 mL/min no significant correlation was found.
Conclusion. A cut-off level for an altered set point of ery-
thropoietin regulation was determined at 40 mL/min creatinine
clearance. Above this cut-off hemoglobin negatively regulates
erythropoietin. Below the cut-off erythropoietin levels remain
stable. Pathophysiologic concepts for this finding and clinical
implications in patients with moderate renal failure are dis-
cussed.
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Hyporegenerative anemia is a common manifestation
of chronic renal failure and considered at least partially
responsible for the symptoms of chronic fatigue and a
reduced general health condition associated with uremia.
The importance of anemia treatment was underlined by
recent studies indicating a reduction in morbidity and
mortality due to a reduced incidence of left ventricular
hypertrophy and consecutive heart failure, a condition
now addressed as cardiorenal syndrome [1, 2]. In addition
data indicating a positive effect of anemia treatment on
the progression of chronic kidney failure were presented
[3], although no large randomized trial on this topic has
been published so far and therefore a recent Cochrane
database review did not support this therapy indication
[4].
With clinical approval of recombinant human erythro-
poietin the treatment of anemia of chronic renal failure
got much less cumbersome and risky than before, when
regular blood transfusion had to be performed. However,
erythropoietin treatment is expensive, and the recently
described pure red cell aplasia due to antierythropoietin
antibodies has raised new questions on its safety [5]. Al-
though the evidence for beneficial effects of anemia treat-
ment in advanced renal failure is overwhelming [6], the
question at what stage of renal dysfunction erythropoi-
etin treatment should be started in order to prevent car-
diovascular complications is still a matter of debate. One
reason for this uncertainty is the lack of a measurable pa-
rameter for inadequate erythropoietin synthesis. Patients
with renal failure may have normal erythropoietin levels
although low for their degree of anemia, a condition ad-
dressed as “relative erythropoietin deficiency.” This study
attempts to establish a quantitative association between
erythropoietin levels and hemoglobin at different levels
of creatinine clearance. Based on this a threshold level of
creatinine clearance is determined, where “relative ery-
thropoietin deficiency” occurs. Possible pathophysiologic
explanations and consequences for anemia treatment are
discussed.
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Table 1. Patient characteristicsa
Group Ab Group Bb Group C Group D Group E All patients
Creatinine clearance mL/minc <20 20–40 40–60 60–90 90–120 0–120
Number 20 89 125 98 63 395
Females number (%) 7 (35) 33 (37) 49 (39) 38 (39) 28 (44) 155 (39)
Age years 63.3 ± 16.3 P < 0.03 72.9 ± 10.3 P < 0.001 72.0 ± 9.1 61.9 ± 9.5 54.4 ± 7.9 66.5 ± 12
Body mass index kg/m2 23.3 ± 6.1 P < 0.001 24.4 ± 3.3 P < 0.001 24.9 ± 3.1 27.2 ± 3.8 30.6 ± 4.4 26.2 ± 4.2
Creatinine clearance 13.5 ± 4.1 P < 0.001 32.1 ± 5.9 P < 0.001 48.2 ± 6.0 75.7 ± 8.7 102.0 ± 7.7 58.2 ± 26.8
Cockcroft mL/min
Glomerular filtration rate 12.0 ± 5.2 P < 0.001 37.3 ± 11.9 P < 0.001 53.6 ± 9.8 69.8 ± 8.1 77.9 ± 10.9 55.8 ± 19.9
MDRD mL/min
Ferritind lg/L (N = 220) 196 ± 100 P = 0.53 136 ± 122 P = 0.2 123 ± 101 142 ± 144 174 ± 150 146 ± 129
Vitamin B12d ng/L (N = 203) 431 ± 286 P = 0.87 327 ± 136 P = 0.05 307 ± 142 346 ± 185 418 ± 246 352 ± 192
Folic acidd lg/L (N = 203) 16.4 ± 43.5 P = 0.35 6.4 ± 3.0 P = 0.32 6.0 ± 2.1 6.8 ± 2.9 5.8 ± 2.8 7.1 ± 12.4
C-reactive proteind mg/L (N = 347) 11.2 ± 14.6 P = 0.01 8.3 ± 9.4 P = 0.02 7.7 ± 15 5.2 ± 4.3 5.1 ± 4.1 6.9 ± 10.7
aValues indicate mean ± standard deviation where appropriate.
bStatistical significance was calculated with unpaired Student t test and is indicated for comparison between group E (normal creatinine clearance) with groups A or
B, respectively.
cCreatinine clearance range in mL/min that was used for definition of groups.
dN = number of patients, for whom the respective laboratory value was available.
METHODS
Patient populations
A total of 5120 consecutive patients were investigated
by coronary angiography at a single center between 1997
and 2001. These patients were prospectively entered in a
registry containing main clinical data, laboratory values,
and results of angiography. For each patient serum sam-
ples were frozen immediately before angiography and
now used for analysis of erythropoietin levels. Patients
on dialysis and/or with previous erythropoietin treatment
were excluded. The opening of the registry and its anony-
mous analysis were approved by the local ethics com-
mittee. In addition, each patient gave written informed
consent for coronary angiography and respective labora-
tory investigations.
For 4760 (93%) of the mentioned 5120 patients
hemoglobin levels and complete information to calcu-
late creatinine clearance according to the Cockcroft for-
mula were available. Data on this population are shown in
Figures 1 and 2A, and we refer to it as the “whole popula-
tion.” These 4760 patients were then stratified according
to the calculated creatinine clearance, and a random sam-
ple of 395 patients was chosen to measure erythropoietin
levels from frozen serum samples. We refer to this popu-
lation as the “sample population,” and data on them are
shown in Figures 2 and 3 and in Table 1.
The sample population of 395 patients was then divided
into five subgroups based on the calculated creatinine
clearance according to Cockcroft (Table 1). The groups
E (clearance >90 mL/min; normal renal function) and D
(clearance 60 to 89 mL/min; mild renal insufficiency) cor-
respond to the staging of chronic kidney disease accord-
ing to the National Kidney Foundation [7]. For groups
C (moderate), B (moderate to severe), and A (severe
renal failure) the cut-off levels for chronic renal failure
suggested by the National Kidney Foundation had to
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Fig. 1. Prevalence of anemia stratified to creatinine clearance within
the whole and the sample population. The prevalence of hemoglobin
level <110 g/L, 110 to 130 g/L, and >130 g/L is shown for the whole
population of 4760 patients and for the sample population of 395 pa-
tients, which were then further analyzed for erythropoietin levels. Bars
indicate percentages of patients with the respective hemoglobin level
within the indicated stratum of renal function. Stratification of renal
function corresponds to that presented in Table 1 and the following
figures.
be changed from 30 and 15 to 40 and 20 mL/min, re-
spectively, for two reasons: (1) group A was consider-
ably smaller than the other groups because coronary
angiography was performed very restrictively in this
patient group due to the high risk of contrast media-
associated renal failure; elevation from 15 to 20 mL/min
allowed adequate sampling of this group; and (2) analy-
sis of the whole data set revealed that pathophysiologic
changes in the erythropoietin response to anemia occur
already at a level of 40 rather than 30 mL/min.
Laboratory values
Erythropoietin was measured in frozen serum
samples in two batches by a solid-phase, two-site
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Fig. 2. Distribution of erythropoietin levels stratified to creatinine
clearance and hemoglobin. The patient cohort was divided into five
different groups according to the calculated creatinine clearance
(mL/min): 90 to 120, normal renal function (N = 1490 in whole/63 in
sample population); 60 to 89, mild renal insufficiency (N = 2319/98); 40
to 59, moderate renal insufficiency (N = 751/125); 20 to 39, moderate
to severe renal insufficiency (N = 151/89); and <20, severe renal failure
(N = 49/20). (A) Levels of hemoglobin (g/L) and erythropoietin (U/L)
in the five different patient groups. (B) Serum erythropoietin levels
(U/L) stratified to the degree of anemia within the five patient groups.
Over each bar the number of patients analyzed in the respective sub-
group is indicated. All bars indicate means ± SEM.
chemiluminescent enzyme immunometric assay on an
Immulite analyzer (DPC, Llanberis, UK). This assay has
a sensitivity of 0.24 mIU/mL and no high dose hook ef-
fect up to 50,000 mIU/mL. Reference values in a healthy
population are indicated as 3 to 30 U/L. There is no
cross-reactivity to a2-macroglobulin, c-globulin, transfer-
rin, and human serum albumin. Total coefficient of vari-
ation is around 6.8%.
Hemoglobin levels, serum creatinine, and in 88% of
patients also C-reactive protein levels were determined
immediately before coronary angiography as part of rou-
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Fig. 3. Distribution of individual erythropoietin and hemoglobin levels
with linear regression analysis. The same patient groups were analyzed
as described in legend to Figure 1. Bold regression lines are valid for the
whole population shown in the respective panel, fine and dotted regres-
sion lines apply to the different subgroups as indicated. Vertical bars
indicate 95% CIs for the bold regression line. (A) Patients with mod-
erate to severe renal insufficiency (creatinine clearance < 40 mL/min)
showed no significant correlation between hemoglobin and erythropoi-
etin levels (r = 0.11, P = 0.25). However, a tendency for a positive slope
of the linear regression line can be observed in both subgroups. (B) Pa-
tients with normal renal function or mild to moderate renal insufficiency
(creatinine clearance > 40 mL/min) showed a significant negative corre-
lation between hemoglobin and erythropoietin (r = −0.35, P < 0.0001).
For all three patient subgroups the slope of the linear regression line is
statistically significant different from zero (P < 0.02), but not different
among each others.
tine clinical workup. The upper normal value for C-
reactive protein was 8 mg/L. Creatinine was measured
by the Jaffe´ method on a Hitachi 917 analyzer (Roche
Diagnostics, Rotkreuz, Switzerland) (age-dependent ref-
erence ranges). Creatinine clearance was then calculated
according to the Cockcroft formula (140 − age [year])
× body weight [kg]/creatinine [lmol/L] with correction
factors ×1.23 for men and ×1.04 for females [8], and
glomerular filtration rate (GFR) was estimated with the
MDRD formula 186 × (creatinine [mg/dL])−1·154 × (age
[years])−0·203 with a correction factor of ×0.742 for fe-
males [9]. In more than 50% of patients, serum ferritin,
folic acid, and vitamin B12 were also measured depend-
ing upon the amount of available material. Ferritin was
measured by MEIA (Abbott, Wiesbaden, Germany)
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(reference range 10 to 400 lg/L), folic acid by ion capture
technology on an Axsym analyzer (Abbott) (reference
range 3.5 to 16 lg/L) and vitamin B12 by chemolumines-
cence on an Immulite 2000 analyzer (DPC) (reference
range 200 to 1000 ng/L).
Statistics
Comparisons between different groups were calcu-
lated by unpaired Student t test. Pearson’s correlation
coefficient r was calculated where indicated. All these
calculations were performed with the statistical software
SPSS (version 11.0). Linear regression lines and there
95% CIs were calculated and plotted with GraphPad
Prism (version 3.03).
RESULTS
Patient characteristics
The sample population of 395 patients was divided
in five different groups based on calculated creatinine
clearance (see Methods section). Patients in groups A
(severe renal failure) and B (moderate to severe renal
insufficiency) were older and had a significantly lower
body mass index when compared to group E (normal re-
nal function). Before analyzing the correlation between
erythropoietin and hemoglobin, we determined addi-
tional parameters in order to exclude other forms of ane-
mia caused by deficiency of iron, vitamin B12, and folic
acid. No significant differences for these parameters were
found between groups A and E. Notably, group A had
even slightly higher levels of vitamin B12, folic acid, and
ferritin indicating that these patients received adequate
supplies of these nutrients. The only significant difference
was observed for vitamin B12 levels between groups B and
E. However, since the mean of group B was still >50%
above the lower reference range, a significant vitamin B12
deficiency is unlikely. C-reactive protein showed signifi-
cantly higher levels in groups A and B compared to group
E. However, the mean levels (group A = 11.2 mg/L and
group B = 8.3 mg/L) were only slightly above the upper
normal value (8 mg/L).
Prevalence of anemia stratified by renal function
Anemia is a feature of renal insufficiency. We therefore
analyzed the prevalence of anemia in the whole popula-
tion of 4760 patients as well as in the sample population,
which was later used to investigate the erythropoietin re-
sponse to anemia. Anemia was defined as a hemoglobin
level <110 mg/L, since this is a level widely used as cut-off
to start erythropoietin therapy (see European Best Prac-
tice Guidelines, [10]). Figure 1 shows two major points:
(1) the prevalence of anemia with hemoglobin <110 mg/L
is around 30% to 40% in patients with severe renal fail-
ure and around 15% in patients with clearance of 20 to
39 mL/min, but rare in the other groups; and (2) the
hemoglobin levels over various degrees of renal failure
is virtually identical between the whole and the sam-
ple population, which supports an adequate sampling of
the patients further used for erythropoietin analysis.
Erythropoietin and hemoglobin levels stratified
by renal function
Analysis of erythropoietin and hemoglobin levels in
groups A to E is depicted in Figure 2A. Groups E (cre-
atinine clearance >90 mL/min) and D (creatinine clear-
ance 60 to 90 mL/min) had identical levels of hemoglobin
and erythropoietin. As expected groups A to C showed
increasing anemia due to progressive renal insufficiency.
However, erythropoietin levels only rose mildly in groups
C and B compared to E (significant only for B, P = 0.04),
but were equal between groups A and E.
We then looked for the response of erythropoietin to
different degrees of anemia within each patient group
(Fig. 2B). As expected, an inverse relationship of erythro-
poietin and hemoglobin levels was found in groups C, D,
and E. However, the erythropoietin response to anemia
was blunted in groups A and B, indicating a relative ery-
thropoietin deficiency already in patients with moderate
renal insufficiency (creatinine clearance <40 mL/min).
Correlation of erythropoietin and hemoglobin
A quantitative correlation of erythropoietin and
hemoglobin was then attempted (Fig. 3). As expected
from Figure 1B, no correlation of erythropoietin and
hemoglobin was found in patients with a creatinine clear-
ance < 40 mL/min (Fig. 3A) (combined groups A and B
r = 0.11, P = 0.25). The slope of the linear regression line
was not significantly different from zero, but tended to
be positive. In contrast a highly significant inverse corre-
lation of erythropoietin and hemoglobin was found for
patients with creatinine clearance >40 mL/min (Fig. 3B)
(combined groups C, D, and E r =−0.35, P < 0.0001). The
slope of the linear regression line was clearly negative and
did not differ between the three subgroups, as indicated
by the regression lines of the individual groups, which
all lied within the 95% CIs. The association of erythro-
poietin with hemoglobin above a creatinine clearance of
40 mL/min can approximately be described by the for-
mula erythropoietin [U/L] = 2.5 × (140 − hemoglobin
[g/L]) or alternatively erythropoietin (U/L) = −2.5 ×
hemoglobin (g/L).
DISCUSSION
Hyporegenerative anemia is a common symptom of
chronic renal failure and has an important impact on
morbidity and mortality of kidney patients. Recently two
large studies with more than 12,000 patients each have
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investigated the incidence of anemia in patients with var-
ious degrees of renal insufficiency and observed a higher
incidence already in patients with moderate renal insuffi-
ciency (creatinine clearance <60 mL/min) [11, 12]. These
results were confirmed in our whole population of al-
most 5000 patients. With recombinant human erythro-
poietin an easy although expensive treatment for renal
anemia is available, but the time point when to initiate
erythropoietin treatment is still a matter of debate, be-
cause no parameter to measure erythropoietin deficiency
is available.
Erythropoietin levels are difficult to interpret in the
context of renal failure. We are aware of only three stud-
ies that investigated erythropoietin levels in relation to
hemoglobin in patients with various degrees of renal in-
sufficiency. Radtke et al [13] measured hemoglobin and
erythropoietin levels in 135 patients with creatinine clear-
ances between 2 and 90 mL/min and found elevated
erythropoietin levels in all five groups compared to con-
trol subjects with normal renal function (creatinine clear-
ance >90 mL/min). Below a creatinine clearance of
40 mL/min erythropoietin levels were inadequate for the
degree of anemia. However, correlation of erythropoi-
etin and hemoglobin within the different groups was not
analyzed in this study. Chandra, Clemons, and McVicar
[14] performed a very similar investigation in 48 children
with various degrees of renal insufficiency. They showed a
significant correlation of hemoglobin and creatinine
clearance below a clearance of 40 mL/min, but again
no analysis of erythropoietin levels at various degrees of
anemia in those groups was shown. Our group recently
presented a small investigation in 17 patients with either
normal renal function (creatinine <100 lmol/L) or mild
renal insufficiency (creatinine 100 to 130 lmol/L) and
found a significantly altered regulation of erythropoietin
in patients with mild renal insufficiency [15]. However,
these results should be interpreted cautiously due to the
small patient sample and the fact that renal function was
analyzed only by serum creatinine.
This study for the first time presents a three-
dimensional quantitative analysis of erythropoietin,
hemoglobin, and renal function assessed by calculated
creatinine clearance in a homogenous population of al-
most 400 patients. The three main findings of this study
are (1) anemia is already observed below a creatinine
clearance of 60 mL/min; this finding is in line with recent
large epidemiologic studies and therefore supports the
adequate sampling of our patient population; (2) inade-
quate erythropoietin synthesis in response to chronic ane-
mia was found below a creatinine clearance of 40 mL/min;
(3) the inverse correlation between erythropoietin lev-
els and hemoglobin above a creatinine clearance of
40 mL/min can be described by the formula erythropoi-
etin [U/L] = 2.5 × (140 − hemoglobin [g/L]) or alter-
natively erythropoietin (U/L) = −2.5 × hemoglobin
(g/L); no correlation was found below this clearance
level.
Erythropoietin secretion is inversely regulated by
hemoglobin levels [16], and the measured parameter is
tissue oxygenation (pO2) in the outer medulla of the
kidney. A low tissue pO2 leads to up-regulation of the
hypoxia-inducible factor-a (HIF-a), a transcription fac-
tor that regulates erythropoietin synthesis [17]. In prin-
ciple, “relative erythropoietin deficiency” in the context
of renal failure may be caused by two different mech-
anisms: either the production capacity of the kidney is
decreased due to the tissue damage by the underlying
disease, or the set point for erythropoietin production is
lowered in relation to tissue oxygenation. Several studies
have shown that the hypoxia-erythropoietin-hemoglobin
feedback system for acute hypoxia is functional in pa-
tients with chronic renal failure. One of the first and
most compelling studies was published 30 years ago. Ery-
thropoietin was measured in six hemodialysis patients at
an altitude of 400 m above sea level, before they were
transported within 5 hours to the alpine research fa-
cility of Jungfraujoch in Switzerland at 3450 m above
sea level, where erythropoietin measurements were re-
peated. An adequate response to the acute drop in in-
spiratory pO2 and therefore tissue oxygenation could
be demonstrated [18]. Another study performed in chil-
dren with creatinine clearance below 20 mL/min found
an adequate erythropoietin increase after acute hypoxic
stress by either pulmonary edema, congestive heart fail-
ure, or sepsis-induced hypotension [14]. These findings,
together with our results, which show that anemia occurs
during early stage of renal failure (creatinine clearance
<60 mL/min), where there is still an inverse relationship
between hemoglobin and erythropoietin (although on a
lower level), strongly support the theory of a lowered set
point for erythropoietin synthesis in patients with renal
failure.
Oxygen consumption and therefore tissue oxygena-
tion in the kidney is mainly determined by the fractional
sodium reabsorption, a highly energy-consuming trans-
port process [19]. Erythropoietin levels were shown to
vary directly with fractional sodium reabsorption in the
context of diabetic nephropathy [20], and blockade of
proximal tubular reabsorption by acetazolamide results
in a drop of erythropoietin levels in normal individuals
[21]. Decreasing hemoglobin and decreasing fractional
sodium reabsorption might therefore represent antago-
nistic stimuli for erythropoietin production in the failing
kidney leading to “normal” erythropoietin levels at the
expense of anemia.
Our results indicate that a lowered set point of ery-
thropoietin synthesis is observed below a creatinine clear-
ance of 40 mL/min. If anemia occurs in this context and
no other reason (as deficiency of iron, folic acid, or vita-
min B12) can be found, erythropoietin therapy should be
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evaluated in order to prevent cardiovascular complica-
tions [1, 22]. For patients with creatinine clearance above
40 mL/min, we have established a quantitative relation-
ship between hemoglobin and erythropoietin for a nor-
mal set point regulation by the formula erythropoietin
[U/L] = 2.5 × (140 − hemoglobin [g/L]) or alternatively
erythropoietin (U/L) = −2.5 × hemoglobin (g/L). In
a given patient this formula could be used to determine
an expected erythropoietin level in the context of a given
degree of anemia and therefore allows the determina-
tion of a state of relative erythropoietin deficiency when
compared with a measured eryhropoietin level.
Since our study was performed in a homogenous pa-
tient population referred because of supposed or proven
coronary artery disease, the main diagnoses for chronic
renal failure may be hypertensive, vascular, and dia-
betic nephropathy. Therefore, it remains to be estab-
lished whether these data can be extrapolated to patients
with glomerulonephritis, interstitial nephritis, congenital
nephropathies or a failing renal allograft.
Taken together, our study shows that an altered set
point of erythropoietin regulation occurs below a crea-
tinine clearance of 40 mL/min. Below this cut-off mea-
surement of erythropoietin is not really useful, since the
response to anemia is blunted. Above this cut-off we sug-
gest a formula to calculate an expected erythropoietin
value, which then can be compared to the effectively mea-
sured level in a given patient in order to determine a state
of relative erythropoietin deficiency. Further prospective
studies have to reveal whether measurement of erythro-
poietin and application of such a formula may be pre-
dictive for the response to exogenous erythropoietin and
the prognosis of renal insufficiency and cardiovascular
events.
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